Difference between revisions of "Vinflunine (Javlor)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Vesicant chemotherapy" to "Category:Vesicant") Tags: mobile edit mobile web edit |
m |
||
| Line 5: | Line 5: | ||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
| − | ==History of FDA | + | ==History of changes in FDA indication== |
Not FDA approved; available in a number of other countries | Not FDA approved; available in a number of other countries | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *9/21/2009: Initial marketing authorization at Javlor. | ||
==Also known as== | ==Also known as== | ||
| Line 20: | Line 23: | ||
[[Category:Bladder cancer medications]] | [[Category:Bladder cancer medications]] | ||
| − | [[Category:EMA approved | + | [[Category:EMA approved in 2009]] |
Revision as of 14:50, 4 December 2021
Mechanism of action
From the NCI drug dictionary: A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.
Diseases for which it is used
History of changes in FDA indication
Not FDA approved; available in a number of other countries
History of changes in EMA indication
- 9/21/2009: Initial marketing authorization at Javlor.
Also known as
- Brand name: Javlor